Topical Calcineurin Inhibitors (TCIs) are drugs administered to treat specific skin conditions, particularly atopic dermatitis or eczema. These medications are directly applied to the affected areas of the skin with the goal of reducing inflammation and combating the immune system’s reaction.
List of topical calcineurin inhibitors
The following are frequently employed Topical Calcineurin Inhibitors:
- Tacrolimus, which is also called Protopic, has received authorization for the treatment of adults and children aged 2 and older with moderate to severe atopic dermatitis.
- Pimecrolimus (Elidel) has received authorization for the treatment of mild to moderate cases of atopic dermatitis in children who are 2 years old and older.
Advantages of Topical Calcineurin Inhibitors:
- TCIs have demonstrated their efficacy in treating the signs of atopic dermatitis, including inflammation, itchiness, and redness of the skin. They can efficiently control flare-ups and improve the overall health and condition of patients.
- TCIs have proven to be effective in dealing with eczema in sensitive regions, such as the facial, neck, and groin areas. Unlike corticosteroids, which can result in undesired reactions, TCIs are a safe alternative for treating these areas.
- TCIs are suitable for extended usage as they remain effective even after prolonged periods, making them an ideal option for continual treatment in chronic conditions such as atopic dermatitis.
Side Effects of Topical Calcineurin Inhibitors:
- Burning and stinging: Certain individuals might feel a brief burning or stinging feeling when they apply TCIs, particularly when they first start using them. However, this sensation usually lessens as time goes on.
- In certain situations, the use of TCIs may cause skin irritation, resulting in the skin becoming red or dry. If these symptoms worsen or continue, it is recommended to discontinue the use of the product and consult a healthcare professional for guidance.
- Although the risk of developing lymphoma is deemed very low, there have been rare instances of patients developing lymphoma while using TCIs. Nonetheless, it is crucial to highlight that the overall risk is still considerably lower compared to using medications that suppress the immune system throughout the body.
Conclusion
Topical Calcineurin Inhibitors are valuable drugs that can effectively and selectively alleviate symptoms of atopic dermatitis. Though they may have some possible adverse effects, when used correctly, they can be a secure and advantageous choice for people with moderate to severe skin conditions.
